Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2023 Sep 14;14:1290431. doi: 10.3389/fimmu.2023.1290431

Corrigendum: Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine

Marina Barrio-Calvo 1, Søren Vester Kofoed 1, Sofie Cens Holste 1, Anders Bundgård Sørensen 1, Nadia Viborg 1, Jens Vindahl Kringelum 1, Daniela Kleine-Kohlbrecher 1, Christian Skjødt Steenmans 1, Christian Bahne Thygesen 1, Birgitte Rønø 1, Stine Friis 1,*
PMCID: PMC10539896  PMID: 37781410

In the published article, there was an error in the Funding statement. The authors inadvertently omitted a funding disclosure that should have been included in the funding section of the manuscript. The correct Funding statement appears below.

Funding Statement

The Innovation Fund Denmark partially funded MB-C (1044-00028B) and NV (5189-00187B). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES